Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
1. Biogen's Q4 earnings of $3.44 beat expectations by 9 cents. 2. Leqembi generated $87 million in Q4, surpassing analysts' expectations. 3. 2025 adjusted earnings guidance fell short, expecting $15.25 - $16.25 versus $16.34. 4. Forecasted revenue decline due to multiple sclerosis competition, offset by new drugs. 5. Cost-cutting aims for $800 million net savings by end of 2025.